Clinical Trials Sponsored by Atlas Biomed

Total 1585 results

Biogen

Completed

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)

Systemic Lupus Erythematosus | Active Cutaneous Lupus Erythematosus

United States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Biogen

Completed

Efficacy and Safety of BG00012 in MS

Multiple Sclerosis

Russian Federation, Sweden, Germany, Poland, Hungary, United Kingdom, Netherlands, Switzerland, Turkey, Czechia
Biogen

Completed

Alternate Dosing Regimens of BG00012 in Healthy Volunteers (109HV106)

Healthy

United States
Biogen

Terminated

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Duomed

Active, not recruiting

A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery (STAP-Delta)

Obesity | Gastrectomy | Roux-en-Y Gastric Bypass | Mini Gastric Bypass

Belgium
Biogen

Approved for marketing

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

United States
Biogen

Completed

Dimethyl Fumarate (DMF) Observational Study (ESTEEM)

Multiple Sclerosis

United States, Denmark, Italy, Netherlands, Switzerland, Canada, Australia, New Zealand, United Kingdom, Slovakia, Austria, Hungary, Czechia, Portugal, Germany, Spain, Poland, Puerto Rico, France, Argentina, Ireland, Norway
Biogen

Terminated

Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (EXPER-CA/IL)

Relapsing Forms of MS

Israel
Biogen

Completed

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

Germany
Biogen

Completed

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Healthy Volunteer

United States
Biocad

Active, not recruiting

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma (FLAT)

Unresectable or Metastatic Melanoma

Russian Federation
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Biocad

Active, not recruiting

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (OBERTON)

Melanoma | Melanoma Metastatic

Russian Federation, Belarus
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
Biogen

Completed

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis | Exposure During Pregnancy

Spain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
Biocad

Completed

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis (BCD-085-7)

Moderate to Severe Plaque Psoriasis

Russian Federation
Biocad

Completed

Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis (SOLAR)

Rheumatoid Arthritis

Russian Federation
Biogen

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Ireland, Netherlands, Switzerland
Duomed

Withdrawn

A Post-market Observational Study With the easyEndoTM Universal Linear Cutting Stapler in Standard Laparoscopic and Robot-assisted Laparoscopic Roux-en-Y Gastric Bypass (RYGB) Surgery (SIRIUS)

Obesity | Roux-en-Y Gastric Bypass

Belgium
Biocad

Completed

Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

Healthy

Russian Federation
Biocad

Completed

Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States
Biogen

Terminated

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)

Alzheimer's Disease

United States, Spain, Italy, Taiwan, Australia, Denmark, Portugal, Korea, Republic of, Canada, Japan, France, United Kingdom, Austria, Germany
Biocad

Completed

International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Russian Federation
Biogen

Completed

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Healthy Volunteer

United States
Biogen

Completed

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
Biogen

Completed

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Healthy

United States
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Spinal Muscular Atrophy

United States
Biocad

Completed

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Russian Federation
Biogen

Completed

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

Glioblastoma Multiforme | Gliosarcoma | Anaplastic Astrocytoma | Oligoastrocytoma, Mixed

United States
Biocad

Completed

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Healthy

Russian Federation
Biogen

Terminated

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease (PRIME)

Alzheimer's Disease

United States
Biogen

Completed

Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) (FORWARD)

Frontotemporal Dementia | Behavioral Variant Frontotemporal Dementia

United States
Biogen

Terminated

Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Supranuclear Palsy, Progressive

United States
Biocad

Completed

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Healthy Subjects

Russian Federation
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Biogen

Completed

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis (IPF)

United States
Biogen

Terminated

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Cognitive Impairment Associated With Schizophrenia (CIAS)

United States
Biogen

Completed

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Healthy

United States
Biogen

Terminated

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Healthy Volunteers

Singapore
Biogen

Completed

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

Healthy

United States
Biogen

Completed

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

Amyotrophic Lateral Sclerosis

Canada, United States, Belgium, Germany, Switzerland, Ireland, Netherlands, France, United Kingdom
Biocad

Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Reticulocyte Count
Biocad

Completed

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Melanoma

Russian Federation
Biogen

Terminated

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (RELAY-1 Extend)

Neuropathic Pain From Lumbosacral Radiculopathy

Spain, United Kingdom, Slovakia, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Italy, Latvia, Romania, Serbia, Estonia
Biogen

Completed

A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia

Trigeminal Neuralgia

United Kingdom
Biocad

Completed

Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®

Leucocytosis

3

Subscribe